What is the primary treatment for nasopharyngeal (nasopharyngial) cancer?

Treatment of Nasopharyngeal Cancer

Primary Treatment Approach

Radiation therapy is the mainstay of treatment for nasopharyngeal cancer, with concurrent cisplatin-based chemotherapy added for locally advanced disease (stage IIB and above). 1

---

Treatment Algorithm by Stage

Early-Stage Disease (Stage I and IIA)

• Radiation therapy alone is the standard treatment for stage I and IIA disease 2, 1
• A total dose of 70 Gy is required for eradication of gross tumor and 50-60 Gy for elective treatment of potential risk sites 2, 1
• Recent high-quality evidence from a 2022 randomized trial demonstrated that IMRT alone is non-inferior to concurrent chemoradiotherapy for low-risk stage II NPC (defined as nodes <3 cm, no level IV/Vb nodes, no extranodal extension, EBV DNA <4000 copies/mL), with 3-year failure-free survival of 90.5% vs 91.9% 3
• IMRT alone resulted in significantly fewer grade 3-4 adverse events (17% vs 46%) and better quality of life during treatment 3

Locally Advanced Disease (Stage IIB, III, and IVA/B)

• Concurrent chemoradiotherapy is mandatory for stage III and IVA/B disease 2, 1
• Concurrent chemoradiotherapy should also be considered for stage IIB disease, with treatment strategies similar to those for stage III-IV often applied 1
• Cisplatin is the standard agent used in concurrent chemotherapy, administered as either 100 mg/m² every 3 weeks or 40 mg/m²/week 2, 1, 4
• The cumulative cisplatin dose should exceed 200 mg/m² total to maximize efficacy 4

Adjuvant and Induction Chemotherapy

• Adjuvant cisplatin and fluorouracil combined with concurrent cisplatin-RT may be beneficial for locally advanced disease 2
• Induction chemotherapy with cisplatin-gemcitabine may be considered for stage III-IVA disease before concurrent chemoradiotherapy, as it improves recurrence-free survival, overall survival, and distant control 4
• However, induction chemotherapy is not considered standard treatment and should not compromise optimal administration of concurrent chemoradiation 2, 1

---

Radiation Therapy Technique

IMRT as the Preferred Modality

• Intensity-modulated radiation therapy (IMRT) is the preferred technique and significantly improves 5-year overall survival and local control compared to conventional 2D or 3D radiotherapy 1, 4
• IMRT offers improvement in local tumor control and reduction in radiation xerostomia in early-stage disease 2, 1
• Daily image guidance with MRI-CT fusion is mandatory for target delineation 4
• A simultaneous integrated boost technique is preferred for convenience and efficiency 4, 5

Critical Dosing Parameters

• Radiation therapy is targeted to the primary tumor and adjacent regions at risk of microscopic spread, as well as both sides of the neck 2, 1
• Elective nodal irradiation is recommended for N0 stage disease 2, 1
• To minimize late toxicity (particularly temporal lobe necrosis), fractional dose should not exceed 2 Gy per daily fraction, and excessive acceleration with multiple fractions >1.6-1.9 Gy/fraction should be avoided 2, 1, 4

---

Treatment of Metastatic Disease

First-Line Systemic Therapy

• Cisplatin plus gemcitabine is the standard first-line treatment for metastatic nasopharyngeal cancer, demonstrating superior overall survival compared to traditional cisplatin/5-FU regimens 6
• Adding immunotherapy (PD-1/PD-L1 checkpoint inhibitors such as camrelizumab or toripalimab) to first-line cisplatin/gemcitabine increases progression-free survival and should be followed by maintenance immunotherapy 6
• In patients with newly diagnosed metastatic disease and adequate performance status, adding locoregional radiotherapy to systemic therapy improves both locoregional control and overall survival 6

Second-Line Treatment

• No standard second-line regimen exists; active agents include taxanes, irinotecan, vinorelbine, ifosfamide, doxorubicin, and oxaliplatin 1, 6
• PD-1/PD-L1 checkpoint inhibitors (nivolumab, pembrolizumab, camrelizumab) demonstrate activity as monotherapy with overall response rates of 20-34% 6
• Expected outcomes with second-line therapy include median progression-free survival of approximately 5 months and median overall survival of approximately 12 months 6

Oligometastatic Disease

• Patients with oligometastatic disease should receive aggressive multimodal treatment including chemotherapy combined with definitive radiotherapy or surgery to metastatic sites, as this approach can achieve long-term survival 6

---

Common Pitfalls and Caveats

Diagnostic and Staging Errors

• Never perform neck biopsy or nodal dissection before definitive treatment, as this reduces cure probability and impacts late treatment sequelae 4
• Complete staging workup should be performed within 1-2 weeks, including MRI of nasopharynx and skull base, FDG-PET for nodal and distant metastatic staging, and baseline EBV DNA levels 4

Treatment Delays and Compromises

• Do not delay treatment for additional biopsies, as the initial endoscopic-guided biopsy is sufficient 4
• Do not compromise the cumulative cisplatin dose during concurrent chemoradiotherapy 4
• If induction chemotherapy is used, do not compromise optimal administration of concurrent chemoradiation 1

Radiation Technique Errors

• Never use conventional 2D or 3D radiotherapy when IMRT is available 4
• Ensure adequate radiation dose to the primary tumor while limiting dose to adjacent critical structures 1

Metastatic Disease Management

• Do not use traditional cisplatin/5-FU as first-line therapy when cisplatin/gemcitabine is available, as the latter has proven superiority 6
• Do not overlook the addition of immunotherapy to first-line chemotherapy in eligible patients 6

---

Follow-Up and Surveillance

• First MRI or PET should be performed at 3 months post-treatment, with PET having higher specificity for differentiating post-radiation changes from recurrence 4
• For T3-T4 tumors, perform MRI every 6-12 months for the first few years 4
• Monitor EBV DNA levels, as persistent elevation after treatment indicates need for additional therapy 4
• Periodic examination should include evaluation of the nasopharynx and neck, cranial nerve function, thyroid function, and systemic complaints to identify distant metastasis 1